β-Adrenergic receptor polymorphisms and response to salmeterol

Michael E. Wechsler, Erik Lehman, Stephen C. Lazarus, Robert F. Lemanske, Homer A. Boushey, Aaron Deykin, John V. Fahy, Christine A. Sorkness, Vernon M. Chinchilli, Timothy J. Craig, Emily DiMango, Monica Kraft, Frank Leone, Richard J. Martin, Stephen P. Peters, Stanley J. Szefler, Wenlei Liu, Elliot Israel

Research output: Contribution to journalArticle

269 Scopus citations

Abstract

Rationale: Several studies suggest that patients with asthmawho are homozygous for arginine at the 16th position of the β2- adrenergic receptor may not benefit from short-acting β-agonists. Objectives: We investigated whether such genotype-specific effects occur when patients are treated with long-acting β-agonists and whether such effects are modified by concurrent inhaled corticosteroid (ICS) use. Methods:Wecompared salmeterol response in patients with asthma homozygous for arginine at B16 (B16Arg/Arg) with those homozygous for glycine at B16 (B16Gly/Gly) in two separate cohorts. In the first, subjects were randomized to regular therapy with salmeterol while simultaneously discontinuing ICS therapy. In the second, subjects were randomized to regular therapy with salmeterol while continuing concomitant ICS. Results: In both trials, B16Arg/Arg subjects did not benefit compared with B16Gly/Gly subjects after salmeterol was initiated. In the first cohort, compared with placebo, the addition of salmeterol was associated with a 51.4 L/min lower A.M. peak expiratory flow (PEF; p = 0.005) in B16Arg/Arg subjects(salmeterol, n = 12; placebo, n = 5) as compared with B16Gly/Gly subjects (salmeterol, n = 13; placebo, n = 13). In the second cohort, B16Arg/Arg subjects treated with salmeterol and ICS concurrently (n = 8) had a lower A.M. PEF (36.8 L/min difference, p = 0.048) than B16Gly/Gly subjects (n = 22) treated with the same regimen. In addition, B16 Arg/Arg subjects in the second cohort had lower FEV1 (0.42 L, p = 0.003), increased symptom scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared with B16Gly/Gly subjects. Conclusions: Relative to B16Gly/Gly patients with asthma, B16Arg/Arg patients with asthma may have an impaired therapeutic response to salmeterol in either the absence or presence of concurrent ICS use. Investigation of alternate treatment strategies may benefit this group.

Original languageEnglish (US)
Pages (from-to)519-526
Number of pages8
JournalAmerican journal of respiratory and critical care medicine
Volume173
Issue number5
DOIs
StatePublished - Mar 1 2006

Keywords

  • Asthma
  • Pharmacogenetics
  • Salmeterol
  • β-adrenergic receptor
  • β-agonists

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'β-Adrenergic receptor polymorphisms and response to salmeterol'. Together they form a unique fingerprint.

  • Cite this

    Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Boushey, H. A., Deykin, A., Fahy, J. V., Sorkness, C. A., Chinchilli, V. M., Craig, T. J., DiMango, E., Kraft, M., Leone, F., Martin, R. J., Peters, S. P., Szefler, S. J., Liu, W., & Israel, E. (2006). β-Adrenergic receptor polymorphisms and response to salmeterol. American journal of respiratory and critical care medicine, 173(5), 519-526. https://doi.org/10.1164/rccm.200509-1519OC